These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6235245)

  • 41. A colorimetric assay for releasable plasminogen activator.
    Campbell EE; Shifman MA; Lewis JG; Pasqua JJ; Pizzo SV
    Clin Chem; 1982 May; 28(5):1125-8. PubMed ID: 6210467
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A sensitive assay for tissue plasminogen activator activity in plasma, using adsorption on lysine-sepharose.
    Gyzander E; Eriksson E; Teger-Nilsson AC
    Thromb Res; 1984 Sep; 35(5):547-58. PubMed ID: 6541374
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glycosylation at Asn-184 inhibits the conversion of single-chain to two-chain tissue-type plasminogen activator by plasmin.
    Wittwer AJ; Howard SC
    Biochemistry; 1990 May; 29(17):4175-80. PubMed ID: 2141793
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasminogen activator/plasmin system: a major player in wound healing?
    Li WY; Chong SS; Huang EY; Tuan TL
    Wound Repair Regen; 2003; 11(4):239-47. PubMed ID: 12846910
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blood cells participate in the fibrinolytic response to tissue-type plasminogen activator.
    Hammouda MW; Moroz LA
    Blood; 1987 Aug; 70(2):564-7. PubMed ID: 3111563
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alpha2-antiplasmin plays a significant role in acute pulmonary embolism.
    Matsuno H; Okada K; Ueshima S; Matsuo O; Kozawa O
    J Thromb Haemost; 2003 Aug; 1(8):1734-9. PubMed ID: 12911586
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusion.
    Bounameaux H; Gresele P; Hanss M; De Cock F; Vermylen J; Collen D
    Thromb Res; 1985 Oct; 40(2):161-70. PubMed ID: 3934784
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Elevated tissue plasminogen activator antigen and stroke risk: The Stroke Prevention In Young Women Study.
    Macko RF; Kittner SJ; Epstein A; Cox DK; Wozniak MA; Wityk RJ; Stern BJ; Sloan MA; Sherwin R; Price TR; McCarter RJ; Johnson CJ; Earley CJ; Buchholz DW; Stolley PD
    Stroke; 1999 Jan; 30(1):7-11. PubMed ID: 9880380
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Importance, localization and functional properties of the cell-associated form of plasminogen activator in mouse peritoneal macrophages.
    Lemaire G; Drapier JC; Petit JF
    Biochim Biophys Acta; 1983 Feb; 755(3):332-43. PubMed ID: 6681715
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Local plasminogen activator and prostacyclin-like activity after partial venous occlusion--an experimental study in the dog.
    Andrade JA; Monteiro AC; Adolfo A; Cabral JM
    Thromb Res; 1988 Jul; 51(1):45-54. PubMed ID: 3046044
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sensitive assay for plasminogen activator of transformed cells.
    Liu HY; Peltz GA; Leytus SP; Livingston C; Brocklehurst J; Mangel WF
    Proc Natl Acad Sci U S A; 1980 Jul; 77(7):3796-800. PubMed ID: 6449002
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modification of invasion and differentiation in human melanoma cell clones.
    Supino R; Cecchi C; Mapelli E; Sanfilippo O
    Melanoma Res; 1994 Aug; 4(4):251-7. PubMed ID: 7950360
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Endogenous tissue plasminogen activator in neonatal cerebrospinal fluid.
    Whitelaw A; Mowinckel MC; Fellman V; Abildgaard U
    Eur J Pediatr; 1996 Feb; 155(2):117-9. PubMed ID: 8775226
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasminogen activator-plasmin system and neuronal migration.
    Moonen G; Grau-Wagemans MP; Selak I
    Nature; 1982 Aug; 298(5876):753-5. PubMed ID: 6213864
    [No Abstract]   [Full Text] [Related]  

  • 55. The effect of modified electroconvulsive therapy on vasopressin release and haemostasis in man.
    Hampton KK; Grant PJ; Boothby M; Dean HG; Davies JA; Prentice CR
    Blood Coagul Fibrinolysis; 1990 Aug; 1(3):293-7. PubMed ID: 2129414
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Influence of Tissue Plasminogen Activator I/D Polymorphism on the tPA Response to Exercise.
    Coughlin AM; Nagelkirk PR; Cooper JA; Paton CM; Friderici KH; Wingerd BA; Pivarnik JM; Womack CJ
    Int J Exerc Sci; 2018; 11(3):1136-1144. PubMed ID: 30338017
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhanced control of bioactivity of tissue plasminogen activator (tPA) through domain-directed enzymatic oxidation of terminal galactose.
    Mahdi WA; Absar MS; Choi S; Yang VC; Kwon YM
    Bioimpacts; 2022; 12(6):479-486. PubMed ID: 36644546
    [No Abstract]   [Full Text] [Related]  

  • 58. Do low and moderate doses of acetylsalicylic acid affect tissue plasminogen activator at rest and after exercise?
    Winther K; Gleerup G; Husted S
    Am J Cardiol; 1994 Apr; 73(9):703-5. PubMed ID: 8166070
    [No Abstract]   [Full Text] [Related]  

  • 59. Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
    Boone NW; van Leeuwen RW
    Clin Ophthalmol; 2012; 6():145. PubMed ID: 22291455
    [No Abstract]   [Full Text] [Related]  

  • 60. Alzheimer's disease prevention & acetyl salicylic acid: a believable story.
    Pomponi M; Pomponi MF
    Indian J Med Res; 2014 Jan; 139(1):1-3. PubMed ID: 24604034
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.